Your browser doesn't support javascript.
loading
Real-world practice in Peyronie's disease management: Results from a national survey of urologists.
Brant, Aaron; Basourakos, Spyridon P; Lewicki, Patrick; Kang, Caroline; Marinaro, Jessica; Punjani, Nahid; Kashanian, James A.
Affiliation
  • Brant A; Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
  • Basourakos SP; Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
  • Lewicki P; Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
  • Kang C; Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
  • Marinaro J; Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
  • Punjani N; Department of Urology, Mayo Clinic, Phoenix, Arizona, USA.
  • Kashanian JA; Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
Andrology ; 11(7): 1320-1325, 2023 10.
Article in En | MEDLINE | ID: mdl-36815582
ABSTRACT

BACKGROUND:

Despite many available treatments for Peyronie's disease (PD), practice patterns of available therapeutics are not well characterized.

OBJECTIVE:

We conducted a national survey of urologists to characterize real-world practice patterns of PD management and to characterize the use of therapies discouraged by the American Urological Association guidelines on PD management. MATERIALS AND

METHODS:

A 34-item survey was distributed via RedCap to urologists who treat patients with PD in all American Urological Association sections. Questions elicited demographic information as well as practices in the diagnosis and treatment of PD. Comparisons were made with Pearson's chi-squared test. The primary outcome was reported use of therapies discouraged by the American Urological Association guidelines on PD.

RESULTS:

A total of 145 respondents completed the survey, of whom 19% were fellowship trained in andrology/sexual medicine, 36% practiced in an academic setting, and 50% had at least 20 years in practice. Only 60% of respondents reporting performing in-office curvature assessment prior to commencing intralesional injection or surgical treatment, with higher prevalence in andrology/sexual medicine fellowship-trained versus non-fellowship-trained urologists (85% vs. 54%, p = 0.003). The most popular treatment modalities were collagenase clostridium histolyticum (61% of respondents), phosphodiesterase-5 inhibitors (54%), and penile traction (53%). Twenty-one percent of respondents reported currently using a treatment that is explicitly discouraged by the American Urological Association guidelines (extracorporeal shockwave therapy for curvature, L-carnitine, omega-3 fatty acids, or vitamin E).

DISCUSSION:

Patients seeking PD treatment may be offered different therapies, some of which are not evidence-based, depending on the treating urologist. This study is limited by self-selection and response bias. Its strength is that it represents a cross-sectional overview of real-world practice patterns in PD management, which has not been previously described.

CONCLUSIONS:

A significant proportion of urologists reported PD management practices that are not evidence-based and not guideline-supported.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Penile Induration / Urologists Type of study: Guideline / Qualitative_research / Risk_factors_studies Limits: Humans / Male Language: En Journal: Andrology Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Penile Induration / Urologists Type of study: Guideline / Qualitative_research / Risk_factors_studies Limits: Humans / Male Language: En Journal: Andrology Year: 2023 Type: Article Affiliation country: United States